Pharmacological enhancement of fear extinction in OCD; a randomized placebo controlled, double blind study. - DCS addition in OCD

Academisch Medisch Centrum0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- All patients meet the DSM-IV criteria for OCD
•- Y-Bocs score: * 18 if obsessions and compulsions; * 12 if only obsessions or compulsions
•- Male and female, aged between 18-70 years
•- Female patients of childbearing potential must have a negative pregnancy test and use reliable method of contraception.
•- Written informed consent
•- Eligible for exposure therapy

•- Presence of any of the following DSM IV conditions:
•* Major depression (HDRS * 15)
•* Bipolar Disorder
•* Schizophrenia or any other psychotic disorder
•* Tic disorder
•* Substance related disorder during the past 6 months
•* Epilepsy or any structural CNS disorder of stroke within the last year;- Presence of primary or co-morbid personality disorder
•- Evidence of clinically significant and unstable cardiovascular, gastrointestinal, pulmonary, Renal, hepatic, endocrine or haematological disorders, glaucoma, myocardial infarction within de past year or micturition abnormalities.
•- Currently taking benzodiazepines
•- Patients at risk for suicide
•- Multiple serious drug allergies of known allergy for DCS
•- Inability to speak Dutch or English

发起方